Quoting Portable Alpha “Management have done a great job developing the pipeline.”
I let the half-year results speak for Peter Idiot: From page 6 of the results: EXPENSES: Research and development expenses were $6,339 (2007: $4,656) reflect the development on partnered and other projects. UP 36% Product development expenses were $6,022 (2007: $5,928), consistent with the advancement of our clinical programs, particularly HRV, LANI and RSV. UP 3%
REVENUE: Research revenue of $4,210 (2007: $4,915) represents fee for services provided as a result of the AstraZeneca and Boehringer Ingelheim collaboration agreements; DOWN 15% Milestone payments of $NIL (2007: $3,419); DOWN 100%
Portable Alpha, Peter Cook is the most useless CEO you can ever find – a PROVEN failure as the CEO of OEC and a total parasite at BTA. Peter Cook is doing such a great job developing the pipeline that research revenue is down 15% and the Milestone payment has dropped to ZERO despite R&D development expenses going up 36%. It is no wonder you are impressed with Peter Cook refusing a $100m settlement offer and then after spending $30m in legal fees sold it for $20m.
BTA Price at posting:
$1.19 Sentiment: Hold Disclosure: Not Held